Old Web
English
Sign In
Acemap
>
authorDetail
>
Mahgull Nazar Thakur
Mahgull Nazar Thakur
Pfizer
Renal cell carcinoma
Axitinib
Medicine
Internal medicine
Dose Modification
3
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.
2021
David I. Quinn
Chi-Fai Ng
Enrique Grande
Tae Gyun Kwon
R. Linke
J-L. Lee
Brad Rosbrook
Mahgull Nazar Thakur
Masatoshi Eto
Marine Gross-Goupil
Show All
Source
Cite
Save
Citations (0)
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
2021
European Journal of Cancer
Michael B. Atkins
Elizabeth R. Plimack
Igor Puzanov
Mayer Fishman
David F. McDermott
Daniel C. Cho
Ulka N. Vaishampayan
Saby George
Jamal Tarazi
William T. Duggan
Rodolfo F. Perini
Mahgull Nazar Thakur
Kathrine C. Fernandez
Toni K. Choueiri
Show All
Source
Cite
Save
Citations (3)
Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.
2019
Journal of Clinical Oncology
David I. Quinn
Tae Gyun Kwon
Masatoshi Eto
Dingwei Ye
Hideaki Miyake
Seong Il Seo
Seok-Soo Byun
Jae-Lyun Lee
Viraj A. Master
Chi-Fai Ng
R. Linke
Brad Rosbrook
Mahgull Nazar Thakur
Enrique Grande
Marine Gross-Goupil
Chao-Hsiang Chang
Show All
Source
Cite
Save
Citations (1)
1